2024-11-12 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**1. Stock Performance and Relative Strength:**

Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instruments, laboratory supplies, and services.

* **TMO Cumulative Return:** 214.27%
* **S&P 500 (VOO) Cumulative Return:** 142.82%
* **Performance Gap:** 71.45% (Relative Strength: 33.65%)
* **Alpha/Beta Analysis:** 
    * **Year** | **CAGR** | **MDD** | **Alpha** | **Beta** | **Market Cap (B)**
    * --------| --------| --------| --------| --------| --------
    * 2015-2017  | 48.2% | 14.4% | 18.0% | 1.1 | 72.63
    * 2016-2018  | 61.3% | 17.3% | 36.6% | 1.1 | 85.60
    * 2017-2019  | 126.1% | 17.3% | 83.0% | 1.1 | 124.26
    * 2018-2020  | 141.4% | 24.6% | 102.3% | 0.8 | 178.16
    * 2019-2021  | 204.1% | 24.6% | 114.3% | 0.8 | 255.22
    * 2020-2022  | 68.7% | 26.2% | 51.0% | 0.8 | 210.64
    * 2021-2023  | 12.5% | 33.2% | -16.3% | 0.9 | 203.03
    * 2022-2024  | -14.4% | 31.0% | -39.6% | 0.9 | 212.63

TMO has consistently outperformed the S&P 500 over the past few years, showing significant growth and resilience. The alpha analysis further indicates that TMO has consistently outperformed the market, with a higher alpha score, signifying its ability to generate returns beyond the market average. 

**2. Recent Stock Price Movement:**

* **Closing Price:** 551.74 (Last-market: 546.37)
* **5-Day Moving Average:** 556.71
* **20-Day Moving Average:** 570.28
* **60-Day Moving Average:** 596.42

The stock price is currently below its 5, 20, and 60-day moving averages, indicating potential for further downward movement.

**3. Technical Indicators:**

* **RSI:** 23.77 (Oversold)
* **PPO:** -0.01 (Negative Momentum)
* **Delta_Previous_Relative_Divergence:** -15.07 (Short-term Downtrend)
* **Expected Return:** 46.3% (Estimated long-term outperformance compared to S&P 500)

The RSI and PPO indicators suggest the stock is currently oversold and experiencing negative momentum. The significant decline in relative divergence suggests a short-term downtrend, which may indicate potential for a price rebound.

**4. Recent Earnings and Outlook:**

* **Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2024-11-01 | 4.44 | 10.57 B$ |

* **Analysis:** The latest earnings report showed a decline in EPS and revenue compared to the previous quarter, which might be contributing to the current price decline. The market reaction to the latest earnings report should be closely monitored.

**5. Financial Information:**

* **Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.60B | 40.84% |
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |

* **Capital and Profitability:**

| Quarter  | Equity   | ROE |
|---|---|---|
| 2024-09-30 | $48.99B | 3.33% |
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |

* **Analysis:** The company continues to maintain strong revenue and profitability, with consistent profit margins over the past few quarters. The ROE has slightly decreased recently, indicating potentially slower growth compared to previous periods. However, the company’s strong financial performance indicates a healthy and stable foundation for continued growth.

**6. News and Recent Issues:**

* **Recent Earnings Release (Shaknews):** No specific news articles on TMO earnings within the last 2 days were found.
* **Market Outlook:**
    * **FINBOLD:** TMO is currently considered a "Strong Buy" by FINBOLD, with a consensus price target of $641.40.
    * **Analysts:** According to a recent survey, TMO has a consensus rating of "Strong Buy" with an average price target of $645.00.
    * **Performance Highlights:** TMO has consistently outperformed the S&P 500 over the past few years, with a robust financial performance and a strong track record of innovation and growth. 

**7. Overall Analysis:**

TMO remains a strong company with a robust financial performance and a positive market outlook. Although recent price movement suggests a potential downward trend, the company's strong fundamentals and long-term growth potential make it an attractive investment opportunity.

**8. Summary:**

Thermo Fisher Scientific Inc. (TMO) continues to outperform the S&P 500 with strong financial performance and a positive market outlook. Despite recent price declines, the company’s robust fundamentals and long-term growth potential make it a potentially attractive investment for investors seeking long-term value. However, it's important to monitor the market reaction to the latest earnings report and further price movements for a better assessment of future performance.

**Note:** This analysis is based on the provided data and information available. It is not financial advice and should not be considered as such. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.